Continue Spironolactone (Aldactone) in HFrEF with Mild Proteinuria
In a patient with heart failure with reduced ejection fraction (HFrEF) and mild proteinuria, spironolactone should be continued as it is established guideline-directed medical therapy (GDMT) with proven mortality benefit, while finerenone lacks FDA approval and robust evidence specifically for HFrEF. 1
Rationale Based on Evidence Hierarchy
Spironolactone: Established Standard of Care
Spironolactone is FDA-approved for NYHA Class III-IV heart failure with reduced ejection fraction to increase survival, manage edema, and reduce hospitalization 1. The landmark RALES trial demonstrated a 30% reduction in all-cause mortality (p<0.001) and a 30% reduction in cardiac hospitalizations in patients with HFrEF 1. This represents Class 1, Level B evidence in the 2022 AHA/ACC/HFSA guidelines 2.
The presence of mild proteinuria is not a contraindication to spironolactone use. In fact, the RALES trial included patients with baseline creatinine up to 2.5 mg/dL and median creatinine clearance of 57 mL/min, demonstrating safety and efficacy across a spectrum of kidney function 1.
Finerenone: Limited Role in HFrEF
Finerenone's evidence base is primarily in:
- HFpEF/HFmrEF (LVEF ≥40%): The FINEARTS-HF trial showed benefit in this population 3, 4
- CKD with diabetes: FIDELIO-DKD and FIGARO-DKD trials 5
Critical limitation: Finerenone is not FDA-approved for HFrEF and lacks dedicated outcome trials in this population. While one propensity-matched analysis suggested potential benefits over spironolactone in cancer patients with LVEF ≥40% 6, this does not establish superiority in classic HFrEF.
Clinical Decision Algorithm
Continue spironolactone if:
- Serum potassium <5.0 mEq/L
- eGFR ≥25 mL/min/1.73 m²
- Patient tolerating current dose
- Monitor potassium every 4 weeks for first 12 weeks, then every 3 months 1
Dose adjustment strategy:
- Start/maintain 25 mg daily
- If intolerant: reduce to 25 mg every other day
- If tolerant at 8 weeks: may increase to 50 mg daily 1
Key Monitoring for Proteinuria
With mild proteinuria present:
- Check baseline and serial potassium levels (higher risk with reduced kidney function)
- Monitor eGFR trajectory
- Assess UACR periodically
- The FINEARTS-HF data showed finerenone reduced albuminuria across kidney risk categories 3, but this does not justify switching from proven mortality-reducing therapy in HFrEF
Common Pitfalls to Avoid
- Do not discontinue spironolactone solely due to mild proteinuria - this is not a contraindication and may actually improve with MRA therapy
- Do not switch to finerenone in HFrEF - you would be moving from proven mortality benefit to unproven therapy in this phenotype
- Do not ignore hyperkalemia risk - the combination of HFrEF, proteinuria, and MRA requires vigilant potassium monitoring (finerenone has 2.07× increased hyperkalemia risk vs placebo 7)
- Do not assume finerenone is "safer" - while it may have lower rates of some adverse events compared to spironolactone in limited data 7, 6, this does not outweigh the lack of mortality data in HFrEF
When to Consider Finerenone Instead
Finerenone would be appropriate if:
- Patient has HFmrEF or HFpEF (LVEF ≥40%) rather than HFrEF
- Concurrent CKD with type 2 diabetes requiring cardiorenal protection 5
- Intolerable side effects from spironolactone (gynecomastia, menstrual irregularities)
Bottom line: The 30% mortality reduction with spironolactone in HFrEF 1 represents one of the most robust benefits in cardiovascular medicine and should not be abandoned without compelling contraindications.